ASTCT and EBMT are proud to present the 6th International Workshop on Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplantation and Cellular Therapy (HSCT²) taking place on November 10 - 11 in Los Angeles, California.
Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation. During the last 5 years significant advances have been made in our understanding of the biology of relapse such as understanding the role of HLA loss in leukemia recurrence post-transplant. Since our 1st relapse meeting we now have three drugs approved to prevent disease recurrence post autologous transplant, and the role of FLT3 inhibitors and other TKIs to prevent relapse post allogeneic HCT is actively ongoing. Finally, the efficacy of CD 19 CAR T cell therapy for patients with disease relapsing after HCT has been firmly established for ALL and NHL.